Академический Документы
Профессиональный Документы
Культура Документы
Review Article
a r t i c l e i n f o a b s t r a c t
Article history: Many inner ear diseases are not adequately treated by systemic delivery of medication. The bloode
Received 17 December 2012 cochlear barrier limits the concentration and size of molecules that leave the circulation and access the
Received in revised form inner ear. This paper reviews the updated status of intratympanic steroid injections (ITS) for the
7 January 2013
treatment of inner ear disease. ITS is a nonaggressive procedure in which high concentrations of
Accepted 14 January 2013
medication reach the cochlea and systemic side effects are minimized. In addition, this procedure is
effective for cochleovestibular symptoms caused by various inner ear diseases including noise-induced
Keywords:
hearing loss, idiopathic sudden sensorineural hearing loss, Ménière’s disease, and autoimmune
Autoimmune inner ear disease
Idiopathic sudden sensorineural
inner ear disease. Although the effect of ITS on noise-induced hearing loss is inconclusive, there is a
hearing loss possibility that its indications could be extended, with a new horizon for pharmacological,
Intratympanic steroid injection neurotrophin, gene, and cell-based therapy.
Ménière’s disease Copyright Ó 2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
Noise-induced hearing loss disease rights reserved.
1016-3190/$ e see front matter Copyright Ó 2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
http://dx.doi.org/10.1016/j.tcmj.2013.01.012
Y.-C. Pai, C.-F. Lee / Tzu Chi Medical Journal 25 (2013) 146e149 147
membrane, loss of drug down to the Eustachian tube, and the Disease Author(s), year Patients, Improvement Improvement
varying pharmacokinetic profiles of medications currently used for n (patient, %) (dB or %)
IT delivery [5]. The round window membrane is the primary Sudden Parnes et al 1999 13 46 62 dB
transfer site for IT therapy. In one study, about one-third of tem- sensorineural [34]
hearing loss Ho et al 2004 [35] 15 53 28 dB
poral bones (i.e., the round window membrane) were obstructed by
Fitzgerald et al 2007 21 67 26.6 dB
a pseudo membrane, fibrous tissue, or a fat plug [44]. Loss of [52]
medication via the Eustachian tube is another anatomic consider- Battaglia et al 2008 120 70 31 dB
ation that may affect the efficacy of IT steroid injection. Results of [53]
animal studies suggest potential ototoxicity of direct steroid Ménière’s Ito and Sakata 1991 61 78 d
disease [27]
application [45]. Persistent tympanic perforation, short-duration Silverstein et al 17 NS NS
vertigo, tinnitus, and otitis media were reported after perfusion of 1998 [30]
high concentrations of steroids [46], but the incidence was very low Garduño-Anaya 22 82 10%
in clinical applications. et al 2005 [28]
[22] Quirk WS, Seidman MD. Cochlear vascular changes in response to loud noise. [37] Plaza G, Herráiz C. Intratympanic steroids for treatment of sudden hearing
Am J Otol 1995;16:322e5. loss after failure of intravenous therapy. Otolaryngol Head Neck 2007;137:
[23] Seidman MD, Quirk WS, Nuttall AL, Schweitzer VG. The protective effects of 74e8.
allopurinol and superoxide dismutase-polyethylene glycol on ischemic and [38] Kakehata S, Sasaki A, Oji K, Futai K, Ota S, Makinae K, et al. Comparision of
reperfusion-induced cochlear damage. Otolaryngol Head Neck Surg 1991;105: intratympanic and intratympanic and intravenous dexamethasone treatment
457e63. on sudden sensorial hearing loss with diabetes. Otol Neurotol 2006;27:604e8.
[24] Puel JL, Pujol R, Tribillac F, Ladrech S, Eybalin M. Excitatory amino acid ana- [39] Banerjee A, Parens LS. Intratympanic corticosteroids for sudden idiopathic
tagonists protect cochlear auditory neurons from excitotoxicity. J Comp sensorineural hearing loss. Otol Neurotol 2005;26:878e81.
Neurol 1994;341:241e56. [40] Ryan AF, Harris JP, Keithley EM. Immune-mediated hearing loss: basic mecha-
[25] Puel JL, Ruel J, Gervais d’Aldin C, Pujol R. Excitotoxicity and repair of cochlear nisms and options for therapy. Acta Otolaryngol Suppl 2002;548:38e43.
synapses after noise-trauma induced hearing loss. NeuroReport 1998;9: [41] Hoffmann KK, Silverstein H. Inner ear perfusion: indications and applications.
2109e14. Curr Opin Otolaryngol Head Neck Surg 2003;11:334e9.
[26] Sendowski I, Abaamrane L, Raffin F, Cros A, Clarençon D. Therapeutic efficacy [42] Yang GS, Song H, Keithley EM, Harris JP. Intratympanic immunosuppressives
of intra-cochlea administration of methylprednisolone after acoustic trauma for prevention of immune-mediated sensorineural hearing loss. Am J Oto-
caused by gunshot noise in guinea pig. Hear Res 2006;221:119e27. laryngol 2000;21:499e504.
[27] Ito A, Sakata E. Treatment of vestibular disorders. Acta Otolaryngol Suppl [43] Ryan AF, Pak K, Low W, Battaglia A, Mullen L, Harris JP, et al. Immunological
1991;481:617e23. damage to the inner ear: current and future therapeutic strategies. Adv
[28] Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, Pane- Otorhinolaryngol 2002;59:66e74.
Pianese C, Rios-Castaneda LC. Dexamethasone inner ear perfusion by intra- [44] Alzamil KS, Linthicum Jr FH. Extraneous round window membranes and
tympanic injection in unilateral Ménière’s disease: a two-year prospective, plugs: possible effect on intratympanic therapy. Ann Otol Rhinol Laryngol
placebo-controlled, double-blinded, randomized trial. Otolaryngol Head Neck 2000;109:30e2.
Surg 2005;133:285e94. [45] Ikede K, Morizono T. Effects of ototopic application of a corticosteroid appli-
[29] Boleas-Aguirre MS, Lin FR, Della Santina CC. Longitudinal results with intra- cation preparation on cochlear function. Am J Otolaryngol 1991;12:151e3.
tympanic dexamethasone in the treatment of Ménière’s disease. Otol Neurotol [46] Jackson LE, Silverstein H. Chemical perfusion of the middle ear. Otolaryngol
2008;29:33e8. Clin North Am 2002;35:639e53.
[30] Silverstein H, Isaacson JE, Olds MJ. Dexamethasone inner ear perfusion for the [47] Plontke SK, Siedow N, Wegener R, Zenner HP, Salt AN. Cochlear pharmaco-
treatment of Ménière’s disease: a prospective, randomized, double-blind, kinetics with local inner ear drug delivery using a three-dimensional finite-
crossover trial. Am J Otol 1998;19:196e201. element computer model. Audiol Neurootol 2007;12:37e48.
[31] Mattox DE, Simmons FB. Natural history of sudden sensorineural hearing loss. [48] Salt AN. Simulation of methods for drug delivery to the cochlear fluid. Adv
Ann Otol 1997;86:463e80. Otorhinolaryngol 2002;59:140e8.
[32] Wilson WR, Byl FM, Laird N. The efficacy of steroid in the treatment of idio- [49] Plontke SK, Wood AW, Salt AN. Analysis of gentamicin kinetics in fluids of the
pathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol inner ear with round window administration. Otol Neurootol 2002;23:967e
1980;106:772e6. 74.
[33] Rauch SD. Intratympanic steroids for sensorineural hearing loss. Otolaryngol [50] Plontke SK, Salt AN. Quantitative interpretation of corticosteroid pharmaco-
Clin North Am 2004;37:1061e74. kinetics in inner ear fluid using computer simulations. Hear Res 2003;182:
[34] Parnes LS, Sun AH, Freeman DJ. Cortocosteroid pharmacokinetics in the inner 34e42.
ear fluid: an animal study followed by clinical application. Laryngoscope [51] Hu A, Parens LS. Intratympanic steroid injection for inner ear disorders: a
1999;109:1e17. review. Audiol Neurootol 2009;14:373e82.
[35] Ho HG, Lin HC, Shu MT, Yang CC, Tsai HT. Effectiveness of intratympanic [52] Fitzgerald DC, McGuire JF. Intratympanic steroids for idiopathic sudden
dexamethasone injection in sudden deafness patient as salvage treatment. sensorineural hearing loss. Ann Otol Rhinol Laryngol 2007;116:253e6.
Laryngoscope 2004;114:1184e9. [53] Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic
[36] Roebuck J, Chang CY. Efficacy of steroid injection on idiopathic sudden dexamethasone þ high-dose prednisolone taper) for the treatment of idio-
sensorineural hearing loss. Otolaryngol Head Neck Surg 2006;135:276e9. pathic sudden sensorineural hearing loss. Otol Neurotol 2008;29:453e60.